Citigroup Maintains Buy on Harpoon Therapeutics, Lowers Price Target to $33
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Yigal Nochomovitz maintains a Buy rating on Harpoon Therapeutics (NASDAQ:HARP) but lowers the price target from $60 to $33.
September 18, 2023 | 1:32 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Citigroup maintains a Buy rating on Harpoon Therapeutics but lowers the price target from $60 to $33.
The news is directly about Harpoon Therapeutics. While the maintained Buy rating is positive, the lowered price target could have a negative impact. The net effect is likely to be neutral in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100